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1543Hypertension is the most common and fatal of the cardio-
vascular risk factors (1), but despite pharmacological ad-
vances, it remains inadequately controlled by medications
(2). Blood pressure (BP) displays substantial heritability
(typically in the range of w30% to 50%) (3), but its genetic
determinants remain largely elusive, a problem referred to as
the “missing heritability” (4). Although rare Mendelian syn-
dromes of familial hypertensionhave beendocumented, usually
in associationwith renal or electrolyte disturbances (5), the bulk
of common heritable BP variation in the population remains
unexplained (6). Genetic-linkage (meiotic cosegregation)
approaches generally possess insufﬁcient resolution for very
complex traits such as hypertension (7), and even recent suc-
cesses in genome-wide association studies have detected loci
with high signiﬁcance but small effect sizes (8).
We took a different approach to genetic determinants of BP
variation in the population: harnessing the power of trait ex-
tremes (9), coupled with pooling for genome-wide association
(10). The use of phenotypic extremes is a powerful approach
both theoretically and practically (11) in genetic association
studies, andgenomic deoxyribonucleic acid (DNA)poolinghas
been an efﬁcient strategy in genome-wide searches for sus-
ceptibility alleles. Here we coupled these 2 strategies, discov-
ering and verifying the role of a novel solute transporter in
association with systemic hypertension.
Methods
Human subjects. Subjects were volunteers, and each subject
gave informed, written consent; the protocols were approved
by the institutional review board. Recruitment procedures,
deﬁnitions, and conﬁrmation of subject diagnoses were
according to previous reports. Genomic DNA of each indi-
vidual was prepared from blood leukocytes. Characteristics
of the 3 human population samples are given in Table 1.
BLOOD PRESSURE: POPULATION TRAIT–EXTREME SAMPLES IN
SAN DIEGO. The power of an association study on trait-
extreme samples was computed (9) under varying disease
allele frequencies for Type I error rate (alpha). We thus
determined that this sample had >90% power to detect
genotype association with a trait if a genotype contributed
as little as 3% to the total variation in men; the power
was even higher in the female cohort. We began by studying
subjects of white (European, by self-identiﬁcation) ancestry,
recruited from a large adult primary care (Kaiser Perma-
nente) population in San Diego, California, as previously
described (9). In this primary care population, w81%
attended the clinic, andw46% consented to participation in
the study, with collection of blood for preparation of
genomic DNA. Subjects who did or did not participate
were similar in self-reported age- and sex-speciﬁc history
of myocardial infarction (men: 4.6% vs. 4.0%; women:
1.4% vs. 1.3%) or in other conditions, including hyperten-
sion, diabetes, obesity, or high cholesterol level. BP was
measured by trained health assistants in the same health
appraisal ofﬁce within a single facility (Kaiser Permanente,Clairemont Mesa Medical Of-
ﬁces, San Diego, California), in
seated subjects with a regularly
calibrated aneroid system, using a
manual BP cuff and auscultation
of the brachial artery at the ante-
cubital fossa. The protocol in-
cludedcuff inﬂation to200mmHg,
with pressure then gradually
released. Systolic blood pressure
(SBP) was recorded as the pres-
sure at which the ﬁrst sound is
heard (i.e., Korotkoff-1), whereas
diastolic blood pressure (DBP)
was recorded as the pressure at
which the sounds disappear (i.e.,
Korotkoff-5). If BP was >150
mm Hg (SBP), >90 mm Hg
(DBP), or both, a second reading
was taken. From consented par-
ticipants, the subjects in this study
were selected, based on measure-
ment of DBP, to represent the
highest- and lowest-ﬁfth DBP
percentiles in that population
(Fig. 1). Subjects were ascertained
by using DBP as the trait because
twin and family studies have
provided evidence that DBP is
substantially heritable (12–14),
and SBP correlates highly with
DBP. In the trait-extreme sub-
jects, there was substantial and
nonoverlapping separation be-
tween both the DBP and SBP
values. A second sampling of
different patients from within BP
extremes of the same population
allowed for replication. The sta-
tistical power of association be-
tween bi-allelic DNA markers
and human quantitative trait loci
can be substantially augmented
by the sampling patients from
opposite (highest and lowest) ends of the trait distribution
(11), and analyses of the quantitative trait in trait-extreme
subjects (as opposed to dichotomization of the trait) further
enhances power (9,15). This population sample afforded us
>90% power to detect genotype association with a trait when
the genotype contributed as little asw2.5% to the total vari-
ation in men (even at p< 10–8); the power was even higher in
women. To accomplish this, lower-BP subjects were selected
from the lowest-ﬁfth percentiles of DBP, whereas the higher-
BP group was selected from the highest-ﬁfth percentiles of
DBP. Both SBP and DBP differed signiﬁcantly between
the BP-extreme groups (p < 0.0001). Forty-one percent of
Table 1
Human Subject Groups Evaluated in this Study of SLC35F3 Genetic Variation and BP,
by Group Genotyped for SLC35F3 (N ¼ 32,063)
Purpose of Study Age, yrs Female Hypertension*
UCSD Twins/Siblings
(n ¼ 616)
“Intermediate” (early) traits 40.0  0.7 71.8 11.2
San Diego (Kaiser)
population BP extremes
(n ¼ 1,994)
Discovery of BP association
(pooled/ individual)
58.2  0.3 60.8 48.0
ICBP
(n ¼ 29,453)
Replication of BP association 49.9  1.1 54.7 32.5
Values are mean  SEM or %. *Deﬁned as SBP 140 mm Hg or DBP 90 mm Hg, or on BP treatment.
BP ¼ blood pressure; ICBP ¼ International Consortium for Blood Pressure Genome-Wide Association Studies; SBP ¼ systolic blood pressure;
UCSD ¼ University of California at San Diego.
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1544patients in the higher-BP group were taking 1 or more
antihypertensive medications (including diuretics and
angiotensin-converting enzyme inhibitors), whereas none in
the lower-BP group were on such treatment. Further BP/
single-nucleotide polymorphism (SNP) association studies
were replicated in an independent sample of different pa-
tients from the same primary health care provider, using the
same recruitment criteria as with the ﬁrst cohort, described
earlier.
EXTENSION OF HYPERTENSION ASSOCIATION INTO AN ADDI-
TIONAL POPULATION SAMPLE: REPLICATION IN INTERNATIONAL
CONSORTIUM FOR BP GENOME-WIDE ASSOCIATION STUDIES.
Extension of associations in our BP-extreme cohorts was
sought in the International Consortium for Blood Pressure
Genome-Wide Association Studies (ICBP), across North
America and Western Europe. Complete details of ICBP
methodology have previously been presented (6). In short,
ICBP data were analyzed separately for SBP and DBP, with
local SLC35F3 region data plotted using LocusZoom
(Center for Statistical Genetics, University of Michigan,
Ann Arbor, Michigan). For the peak BP-associated SNP inFigure 1 Population BP Extremes: A Powerful Approach to Genotype
Blood pressure (BP) distribution in a primary care database of over 53,000 adults (27,478
extremely high and low diastolic BP (DBP) (from the upper and lower ﬁfth percentiles of DBP
variance. Red rectangles ¼ DBP range for upper- and lower-percentile (extreme) samplethe second intron (rs16842784; C > A), the numbers of
available ICBP subjects for SBP/DBP were 27,865 and
29,452, respectively.
TWIN PAIRS AND SIBLINGS FOR AUTONOMIC AND CARDIAC
PHENOTYPING (UNIVERSITY OF CALIFORNIA AT SAN DIEGO).
From 235 nuclear families, 399 subjects including twin and
sibling pairs were recruited from southern California to
participate in the study. Zygosity was conﬁrmed by extensive
microsatellite and SNP genotyping, as described (16). Twins
ranged in age from 15 to 84 years; 10% were hypertensive.
Thus, the twin/sibling analyses were adjusted for sex and
age. All of the twins in these allelic/haplotype association
studies were self-identiﬁed as being of European (Cauca-
sian) ancestry.
CARDIAC AND VASCULAR FUNCTION. Baseline/resting cardio-
vascular traits (SBP, DBP, heart rate [HR], cardiac index
[CI], and systemic vascular resistance index [SVRI]) were
estimated in twins/siblings noninvasively using the Dyna-
Pulse oscillometric device (PulseMetric, Vista, California),
as previously described (17). Flow parameters (cardiacs Underlying Hypertension
women; 25,528 men). We ascertained age-, sex-, and ethnicity-matched subjects with
distribution); this approach has >90% power to detect loci contributing >2.5% of BP
selection. Trait extremes method from Schork et al. (11).
JACC Vol. 63, No. 15, 2014 Zhang et al.
April 22, 2014:1542–55 Genetics and Hypertension
1545output [CO], SVR) were normalized to body surface area, to
yield CI and SVRI. The correspondence between Dyna-
Pulse and more conventional or invasive determinations of
CO and SVR were documented recently (18).
ENVIRONMENTAL (COLD) STRESS TEST. To probe the func-
tional signiﬁcance of common variation at SLC35F3, we
examined the potential inﬂuence of polymorphisms on BP
response during an environmental (cold) stress test (19) in 399
twin (monozygotic or dizygotic) and sibling subjects.During the
stressor, the subject immersed the nondominant hand into ice
(0C) water for 1 min, with averaged measurements of SBP,
DBP, and HR stable over 3 beats pre- and post-procedure.
AUTONOMIC NEURAL FUNCTION. Sensitivity of the barore-
ceptor reﬂex arc (in ms/mm Hg) was tested by the ramp
(time domain) method, using spontaneous excursions of
SBP upward (with reﬂex bradycardia) and downward (with
reﬂex tachycardia), as described (20,21). BP (in mm Hg)
and pulse interval (R-R interval or heart period, in ms/beat)
were recorded continuously and noninvasively for 5 min in
seated subjects with a radial artery applanation device and
dedicated sensor hardware (Colin Pilot, Colin Medical In-
struments Corporation, San Antonio, Texas) and software
(ATLAS, WR Medical Electronics Company, Stillwater,
Minnesota; Autonomic Nervous System, Tonometric Data
Analysis, Colin Medical Instruments Corporation) cali-
brated every 5 min against ipsilateral brachial arterial pres-
sure with a cuff sphygmomanometer. HR was recorded
continuously with thoracic electrocardiographic electrodes to
the Colin Pilot. BP and HR were recorded continuously
with the same devices during spontaneous excursions of BP
with reciprocal HR changes: upward excursions of BP with
reﬂex bradycardia and downward excursions of BP with
reﬂex tachycardia. In each case, baroreceptor slope in the
“time domain” was calculated with the Autonomic Nervous
System, Tonometric Data Analysis software, with beat-
by-beat regression of change in pulse interval (R-R inter-
val; ms/beat) as a function of change in SBP (mm Hg) on
the preceding beat (phase lag: 1 beat). Time windows of >4
beats were used, with change in SBP of >1 mm Hg and
change in R-R of >6 ms. Baroreceptor slope (ms/mm Hg)
values were recorded for regressions with correlation co-
efﬁcients (r) > 0.9. The slopes for 3 such regressions, if each
was within 10% of the mean value, were averaged to yield
the ﬁnal value for baroreceptor slope.
SECRETONEURIN ASSAY. Human plasma treated with ethyl-
enediaminetetraacetic acid as an anticoagulant was frozen
and stored at –70C prior to assay. The biologically active
secretoneurin fragment of human SCG2 (TNEIVEE-
QYTPQSLATLESVFQELGKLTGPNNQ) was measured
by radioimmunoassay, as previously described (22), with a
rabbit polyclonal antibody directed against synthetic human
secretoneurin (SCG2154–165) and iodination on the endoge-
nous tyrosine. The assay sensitivity in plasma was<40 pmol/l,
with a reference range of <220 pM (<0.22 nM).Genome-wide association. The rationale, methodology,
and quality metrics for the pooling approach to genome-wide
association have been presented in detail (10). Brieﬂy, we
formed representative DNA pools from 4 groups of subjects
with the most extreme (highest- and lowest-ﬁfth percentiles)
of BP in a large primary care population: highest male (n ¼
277), highest female (n ¼ 283), lowest male (n ¼ 241), and
lowest female (n ¼ 330). Genomic DNA was prepared from
blood leukocytes in each individual, then quantiﬁed by
PicoGreen ﬂuorescence (Molecular Probes, Inc., Eugene,
Oregon), and then equivalent amounts of DNA from each
individual were incorporated into each of the 4 pools. The
quality of the pooled DNA was veriﬁed by appearance on
1% agarose gel followed by ethidium bromide staining. The
4 pooled DNA samples were then hybridized (after digestion
with either Nsp I or Sty I) to replicate Affymetrix 5.0
(w500 K) SNP arrays (Affymetrix, Inc., Santa Clara, Cali-
fornia) (4 arrays per pooled sample). In addition, the same
samples were hybridized to replicate HumanHap300
(w300 K) SNP arrays (Illumina, Inc., La Jolla, California).
Relative allele scores were calculated for bi-allelic SNPs
using the formula A/(A þ B), where A ¼ major allele and
B ¼ minor allele, to highlight the most signiﬁcantly asso-
ciated SNPs. Relative allele scores were calculated in the
higher- versus lower-BP groups, which were then ranked for
each SNP. SNP loci with relative allele scores most different
between extreme cases and extreme controls, for both the
Affymetrix 5.0 and Illumina HumanHap300, were pursued
further. First, we ranked all SNPs by their allele-frequency
differences between the 2 BP groups. Second, we took the
top 250 SNPs from each array (Affymetrix and Illumina)
and computed the absolute (in base pairs [bp]) distances
between each neighboring SNP in these top lists. For those
SNPs that were on different arrays but were ranked in the
top 250 SNPs and that had a nearby neighbor SNP from the
opposite array, we ranked (Online Table 1) and selected
candidates for follow-up replication genotyping, resulting in
5 selected SNP pairs. Because the initial decision for locus/
SNP follow-up was based on genotyped pools, standard
statistical tests were not applicable at this stage.
Individual SNP genotyping. Diploid rs17514104 (SLC35F3
tagging SNP in intron 2: TGGAA[C/T]TTGAC; alleles
C>T) or rs16842784 (C>A, also in intron 2) genotypes were
determined by either of 2 extension-based techniquesdthe
matrix-assisted laser desorption ionization mass spectrometry
method of Sequenom, Inc. (La Jolla, California), or the lumi-
nescent base incorporation method of Pyrosequencing
(Biotage, Qiagen, Germantown, Maryland), in which
genotypes were veriﬁed by visual inspection, with exclusion of
artefactual data from further analysisdor by the TaqMan
primer/probe system (Premier Biosoft, Palo Alto, California)
on an ABI-7900HT device (AB Sciex, Foster City,
California [formerly Applied Biosystems]). Reproducibility
of diploid genotypes was veriﬁed with blinded replicate
samples, indicating 98.8% concordance. In the twin/sibling
sample, genotypes were acquired as part of a genome-wide
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1546scan (Illumina-610-Quad; Illumina, Inc.) and veriﬁed in
each subject by TaqMan. rs17514104 Diploid genotypes
were in Hardy-Weinberg equilibrium (chi2: 0.001; p ¼
0.966; minor allele frequency [MAF]:w27%–28%). Human
SLC35F3 genetic variants considered in this study are tabu-
lated in Online Table 2.
Statistics and bioinformatics. STATISTICS. Estimates are
stated as mean  1 SD. Traits that were not normally
distributed were log10-transformed prior to parametric data
analyses. Two-way analysis of variance (ANOVA) or
multivariate general linear modeling, as well as post-hoc
corrections, were performed in SPSS version 11.5 (IBM
SPSS Statistics, IBM Corporation, Armonk, New York) to
evaluate the signiﬁcance of single variants during in vivo
association studies as well as in vitro transporter activity.
During marker-on-trait associations in vivo, results of
descriptive statistics (mean  SEM for each diploid geno-
type) were plotted in order to select the optimal model
(additive vs. dominant/recessive) for inferential statistical
testing (F, chi-square, p). BP analyses were adjusted for age
and sex, as well as the effects of antihypertensive treatment,
by adding a ﬁxed value (10/5 mm Hg) to each treated BP, as
described (23); although such adjustments are necessarily
imperfect, their value is reinforced by restoration of familial
(sibling/sibling) BP correlations (23). Parametric, general
linear model (typically, 2-way ANOVA) analyses tested
associations of SLC35F3 diploid genotypes and continuous
BP traits (mm Hg). Dichotomous variables (e.g., hyper-
tension) were analyzed by proportions and chi-square test.
For twin pair analyses, descriptive (genotype-speciﬁc mean
 SEM) and inferential (chi-square, p value) statistics were
computed across all of the twins using generalized esti-
mating equations (PROC GENMOD) in SAS (SAS
Institute Inc., Cary, North Carolina) or SPSS, to account for
correlated trait values within each twinship, using an
exchangeable correlation matrix (24). In twin pairs, herita-
bility (or the fraction of trait variance accounted for by
genetic variance [h2 ¼ VG/VP]) was estimated by Sequential
Oligogenic Linkage Analysis Routines (SOLAR) software
(Texas Biomedical Research Institute, San Antonio, Texas)
(25). Haplotypes were imputed from unphased diploid
genotypes on the SLC35F3 region using an expectation-
maximization algorithm in PLINK version 1.07 (Harvard
University, Cambridge, Massachusetts). Meta-analyses
were carried out with the command META, testing ﬁxed-
effects (i.e., genotype as independent variable) models in
STATA-12 (StataCorp LP, College Station, Texas), after
individual study regression analysis in SPSS or R, incorpo-
rating individual study data to derive signiﬁcance as well
as pooled genotype effect size (beta, or slope per allele) and
its SE.
FALSE DISCOVERY RATE. In consideration of testing the ef-
fects of multiple correlated alleles (or diploid genotypes) at a
locus on a trait, we employed estimation of the false dis-
covery rates in order to minimize false negative results whilemaximizing true positive results, using the Excel calculator
of false discovery rates from p values (Microsoft Corpora-
tion, Redmond, Washington).
ALTERNATIVE MRNA SPLICING. Based on transcript and
expressed sequence tag (short messenger ribonucleic acid
[mRNA]/ complementary DNA [cDNA] fragment) ev-
idence (with sequence data processing according to Florea
et al. [26]), computationally derived alternative splicing
patterns were viewed.
SLC35F3 FUNCTIONAL AND STRUCTURAL PREDICTIONS.
Transporter homology predictions were conducted within
the Transporter Classiﬁcation DataBase (TCDB) (Saier Lab-
oratory Bioinformatics Group, University of California, San
Diego, California), evaluating sequence similarity as well as
functional classiﬁcation and likely orthologs, paralogs, and
membrane-spanning secondary structures. Amino acid se-
quence alignments were conducted in Clustal-W (now Clustal
Omega, European Molecular Biology Laboratory, Wellcome
Trust Genome Campus, Hinxton, United Kingdom). Cellular
localization (organelle) targeting sequences were evaluated
using TargetP (Center for Biological Sequence Analysis,
Technical University of Denmark, Lyngby, Denmark).
SLC35F3 AND THIAMINE METABOLISM. SLC35F3 EXPRESSION.
ThehumanSLC35F3 full-length cDNA(UniGeneHs.158748,
RefSeq mRNA XM_001132419.1, Image clone 5273868, Na-
tional Center for Biotechnology Information [NCBI] accession
BC037878.1, IRAK75-e24) was obtained from Geneservice
Ltd. (Cambridge, United Kingdom) in pBluescript-R, and
subcloned into the prokaryotic expression plasmid pZE12luc
(27), under the control of the PLlacO-1 promoter. Escherichia coli
strain MW25113 (with endogenous thiamine transport
[ThiBPQ ¼ sfuABC] and biosynthetic [ThiH] genes inacti-
vated) was transformed by this plasmid, under selection by
ampicillin, with expression of SLC35F3 triggered by 1-mM
isopropyl b-D-1-thiogalactopyranoside (IPTG).
THIAMINE UPTAKE CATALYZED BY SLC35F3. Thiamine [3H(G)]
hydrochloride, at 10 to 20 Ci/mmol (0.37–0.74 TBq/mmol)
was obtained from American Radiolabeled Chemicals
(ART-0710; St. Louis, Missouri). The uptake protocol
followed our previous studies (28), with modiﬁcations as
noted here. E. coli grown in minimal medium (M9 with
0.2% glucose, 100-ng/ml ampicillin, and 1-mM isopropyl
b-D-1-thiogalactopyranoside [IPTG]) was harvested in the
exponential growth phase, pelleted and washed once in ice-
cold M9 medium, and resuspended in M9 (plus 0.2%
glucose), with cell density adjusted to optical density at
500 nm (OD500) ¼ 1 (light scattering). [3H]-thiamine was
added at 20 nM, and uptake studies were conducted at
18C; in an initial kinetic experiment (time course), cellular
net uptake of [3H]-thiamine, catalyzed by SLC35F3 ex-
pression, was maximal by 5 min. Aliquots (100 ml) were
periodically removed from the 1-ml cell suspensions, diluted
15-fold with M9 buffer, ﬁltered (0.45-mm ﬁlters [Millipore
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1547Corporation, Billerica, Massachusetts]) and washed twice
with the same buffer. After the ﬁlters were dried under a
heat lamp for 15 min, radioactivity was measured by scin-
tillation counting using 10 ml of Biosafe NA scintillation
ﬂuid (Research Products International, Mt. Prospect, Illi-
nois). Uptake activity attributed to SLC35F3 alone was
obtained by subtracting the activity remaining in the absence
of SLC35F3 function from the cDNA-expressed activity,
assuming that the absence of SLC35F3 does not activate
some other transporter.
HUMAN ERYTHROCYTE THIAMINE (VITAMIN B1) DETERMINATION.
Blood was obtained from subjects of known diploid genotype
at SLC35F3 rs17514104, speciﬁcally major allele (C/C) and
minor allele (T/T) homozygotes, into ethylenediaminetetra-
acetic acid anticoagulant tubes, whereupon whole blood was
frozen at –70C prior to thawing and thiamine assay by a
microbiological method, as described (29,30), wherein a
thiamine–growth-dependent strain ofLactobacillus fermentum
is used on a coated 96-well microtiter plate in a commercial
spectrophotometric kit (Immundiagnostik AG, Bensheim,
Germany). After incubation at 37C for 48 h, the growth of
Lactobacillus fermentum is measured turbidimetrically at
630 nm in an enzyme-linked immunosorbent assay spectro-
photometric reader, and a standard curve is generated from the
dilution series. The amount of vitamin B1 is directly propor-
tional to the turbidity. Assay standards ranged from 0 to 15
mg/l, and blood samples were typically assayed in duplicate or
triplicate at 1:10 dilution. The results correlate well with high-
performance liquid chromatography methods (r: 0.886), and
the coefﬁcients of variation were 2.75% (intra-assay; n ¼ 28)
and 3.81% (interassay; n ¼ 5). Results are expressed in mi-
crograms per liter of blood.
ALLELIC EXPRESSION IMBALANCE AT THE SLC35F3 LOCUS. The
rationale for the allelic expression imbalance (AEI) approach
was detailed by Pastinen (31); brieﬂy, AEI was employed to
provide evidence that a cis-quantitative trait locus (QTL) (in
particular, a cis-eQTL for mRNA expression) exists at the
SLC35F3 locus; that is, the abundance of SLC35F3 tran-
scripts is tested for dependence on the diploid genotype
(both alleles) at the same locus encoding the transcript.
HUMAN AEI. From 53 CEU (Caucasian of European descent)
lymphoblastoid cell lines, genomic DNA and double-
stranded cDNA were used for the parallel genotyping and
AEI analysis on Inﬁnium Human1M or Human1M-Duo
SNP bead microarrays (Illumina, Inc., La Jolla, California),
as described (32). Brieﬂy, the results of SNP genotyping and
allelic transcript ratios, as deﬁned by averaging across all
measured SNPs in each sample for the annotated transcripts,
were coupled by linear regression to discover cis-acting
regulatory SNPs. Prior to averaging allele ratios across each
transcript, we applied a polynomial normalization to account
for intensity-dependent variation in allelic expression ratios
observed in cDNA samples, as previously described (33).
Multiple testing was addressed by permutation tests at thetranscripts; based on permutation tests, signiﬁcance of p< 1E-7
was considered genome-wide signiﬁcant, as deﬁned by a false
positive rate ofw50 to 100per 10,000measured transcripts (32).
RODENT (MOUSE) AEI. AEI in mouse strains was measured
using F1 animals generated from 4 inbred strains with
known genetic sequence. Six F1 strains (all possible pairings)
were generated from parental strains A/J (A), C3H/HeJ (C),
C57BL/6NJ (B), and DBA/2J (D). Liver RNA was
obtained from 6 male F1 animals from each F1 strain. The
RNA from these 6 animals was pooled into 2 groups of 3,
which were hybridized to the mouse diversity array (34), a
genotype array containing 600,000 SNPs polymorphic in
mouse strains. The genomic DNA from each of the F1s
was also hybridized to the mouse diversity array. By com-
paring the different levels of relative intensity of the alleles in
the genomic DNA to the intensity of the alleles in the RNA,
we can measure the amount of AEI in each F1 strain.
Results
Genome-wide association: population BP-extreme samples
in San Diego. Based on relative allele scores in the higher-
BP group versus the lower-BP group, on both the Affyme-
trix 5.0 (w500 K) and Illumina HumanHap300 (w300 K)
SNP array hybridizations, the variants within each sex analysis
were then ranked by allele-frequency differences and priori-
tized for validation genotyping. At this point, results of
pooling were not amenable to standard statistical testing.
Tagging SNPs were then selected for further study by in-
dividual genotyping in the original (unpooled) population
BP-extreme samples (from which the pools had been for-
med). Because individual genotyping results on SLC35F3
(a w420-kbp locus on chromosome 1q42) achieved statis-
tical signiﬁcance with BP, that locus was selected for
additional evaluation. The BP-associated region of
SLC35F3, as deﬁned by tag SNPs, was within intron 2 of
this w420-kbp locus.
SLC35F3 tag SNP rs17514104 (MAF: w27% to 28%)
was typed in not only the original population BP-extreme
individual samples, but also in subjects from a second BP-
extreme sample from the same source population. In these
samples, examination of the distribution of diploid geno-
types by BP status (highest, lowest) (Fig. 2A) revealed an
over-representation of T/T (minor allele) homozygosity
among hypertensive subjects, with a corresponding depletion
of C alleles (among C/C minor allele homozygotes or C/T
heterozygotes) in the normotensive subjects (p ¼ 2.9E-02).
When BP was evaluated as a continuous trait (Fig. 2B), T/T
homozygotes displayed parallel elevations in both SBP
and DBP (p ¼ 1.6E-02 and p ¼ 3.0E-02, respectively).
Meta-analysis indicated that the genotype effects were
directionally consistent in each San Diego population sam-
ple, for both SBP and DBP (both, p ¼ 1.9E-02) (Table 2).
EXTENSION OF BP ASSOCIATION TO SLC35F3 IN ICBP. The
ICBP program allowed replication into an additional
Figure 2
SLC35F3 Tagging Variants: Effects on BP in
Population-BP-Extreme Subjects, and Replication
Each of the 2 tagging variants is located within the same linkage disequilibrium
block in SLC35F3 intron 2. Effects of rs17514104 on (A) blood pressure (BP)
status (hypertensive [HT] or normotensive [NT]) as a dichotomous trait (chi-
square) and (B) systolic and diastolic BP (SBP and DBP, respectively) as
quantitative traits (mm Hg) (analysis of variance [ANOVA], adjusted for age and
sex). (C) Effect of rs16842784 on SBP and DBP as quantitative traits (mm Hg)
(ANOVA, adjusted for sex and age). HWE ¼ Hardy-Weinberg equilibrium.
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western Europe); inspection of the trait-associated region of
SLC35F3 (by LocusZoom plot) (Online Fig. 1) revealed
peak BP association in SLC35F3 intron 2 at rs16842784,
which is 17,474 bp downstream (30) of previous tag SNP
rs17514194 (D0: 1.0 in HapMap CEU) (Online Table 2)
and within the same linkage disequilibrium (LD) block, as
judged by the cM/Mb tracing. Thus we typed rs16842784
(C > A; MAF: w0.7%–0.8%) in the original San Diego
subjects and found that the BP associations were signiﬁcant
for SBP and DBP in both ICBP (p ¼ 4.18E-04 and p ¼
1.64E-04, respectively) and the San Diego BP extremes
(p ¼ 1.10E-02 and p ¼ 8.00E-03); subsequently, meta-
analysis documented the replication for both SBP and
DBP, at p < 1.00E-04 and p < 1.00E-04 (Table 3).
Figure 2C plots the effects of rs16852784 on SBP and
DBP in the San Diego BP-extreme samples. Effects on SBP
and DBP were signiﬁcant, at p ¼ 5.01E-03 and p ¼ 5.00E-
03, respectively, and the effect of the minor/A allele was to
decrease SBP and DBP by w13 and w10 mm Hg. The
proportions of trait variance (R2) explained by rs16852784
in the San Diego population sample on SBP and DBP were
0.063% and 0.096%, highlighting the substantial difference
between the effect of a relatively rare (here, MAF: w0.8%)
genetic variant on the trait in subjects segregating the allele
(Fig. 2C) versus the effect in the overall population (R2).
SLC35F3 HAPLOTYPE AND BP: POPULATION BP-EXTREME SAM-
PLES IN SAN DIEGO. Because SLC35F3 genotype data from
both rs16842784 and rs17514104 were available and in LD
(D0: 1.0) (Online Table 2), we also examined the effects of
rs16842784 (C > A; MAF: w0.8%)/ rs17514104 (C >
T; MAF: w28%) haplotypes on BP. Haplotypes C / C
(w71.9%), A/ C (w27.6%), and C/ T (w0.5%) were
observed, whereas doubly minor allele haplotype A / T
was not observed (0%). By regression on the BP traits, the
rarest haplotype, C / T, had strong effects on both SBP
(p ¼ 0.00103) and DBP (p ¼ 0.00031), whereas haplotype
A / C had more modest effects on the traits (SBP: p ¼
0.025; DBP: p ¼ 0.039), and the most common haplotype,
C/ C, did not inﬂuence BP.
Bioinformatic analyses of SLC35F3: homology to a
thiamine transporter. Within the TCDB international
consensus system, human SLC35F3 (UniProt Q8IY50) is a
member of the drug/metabolite transporter (category 2.A.7)
superfamily of membrane transporters (SLC35F3 classiﬁ-
cation in TCDB: 2.A.7.24.8).
Sequence similarity analyses within that TCDB group
indicate that the closest homologuewith functional data is likely
to be transporter 2.A.7.24.1, initially represented by Thi74 of
yeast (Saccharomyces cerevisiae), known as a thiamine-repressible
mitochondrial membrane protein (UniProt Q04083; yeast
locus YDR438W), although Q04083 did not possess a classic
mitochondrial targeting sequence, when tested using TargetP,
indeed, Q04083 possessed a hydrophobic amino terminus
typical of a signal peptide for the secretory pathway or cell
Table 2
Effects of SLC35F3 Intronic Variant rs17514104 on the Quantitative BP Traits (SBP and DBP, in mm Hg) in
2 Independent Population Samples: Meta-Analysis
Group Alleles, Minor/Major MAF, % n Trait Model Beta (Slope per Allele) SE (of Beta) p Value
KWE1 T/C 27.6 922 SBP T-recessive 3.492 1.691 –
KWE2 T/C 27.3 1.072 SBP T-recessive 1.823 1.328 –
Meta-result T/C 27.5 1.994 SBP T-recessive 2.460 1.044 1.90E-02
KWE1 T/C 27.6 922 DBP T-recessive 1.612 1.392 –
KWE2 T/C 27.3 1.072 DBP T-recessive 1.979 0.964 –
Meta-result T/C 27.5 1.994 DBP T-recessive 1.860 0.792 1.90E-02
Covariates in these analyses were age and sex, and BP values in the hypertensive subjects were adjusted for medications, as described in the Methods section.
BP ¼ blood pressure; DBP ¼ diastolic blood pressure; KWE1 ¼ ﬁrst population BP-extreme sample; KWE2 ¼ second population BP-extreme sample; MAF ¼ minor allele frequency; SBP ¼ systolic blood
pressure.
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VVVVFWV. Sequence homologies between the 2 proteins are
tallied in Online Table 3, and secondary structure predictions
are given inOnline Figures 2A and 2B. Each protein is likely to
give rise to 10membrane-spanning (hydrophobic) domains, in
a “2 þ 8” conﬁguration, with the most amino-terminal
2 hydrophobic domains somewhat displaced from the
remaining 8 hydrophobic domains by a relatively long
hydrophilic intervening sequence (between the ﬁrst 2 and the
ﬁnal 8 hydrophobic domains).
Thiamine metabolism studies. [3H]-THIAMINE UPTAKE
CATALYZED BY HUMAN SLC35F3 PROTEIN EXPRESSION IN E. COLI.
To test whether human SLC35F3 can catalyze thiamine
transport, we expressed its cDNA in anE. coli strain (previously
disabled for thiamine uptake [ThiBPQ] or synthesis [ThiH];
see Methods section), and evaluated cellular uptake of [3H]-
thiamine.During SLC35F3 expression, [3H]-thiamine uptake
rose substantially, byw3.3-fold (p ¼ 3.4E-04) (Fig. 3A).
THIAMINE CONTENT OF HUMAN ERYTHROCYTES. STRATIFI-
CATION BY SLC35F3 GENOTYPE. We measured thiamine in
subjects stratiﬁed by previously determined rs17514104
genotype, either major allele (C/C) or minor allele (T/T)
homozygotes. Subjects with the T/T (i.e., hypertension-
associated) genotype displayed a signiﬁcant reduction in
blood thiamine content, from 114.5  0.63 mg/l to 101.2 
0.69 mg/l (p ¼ 3.0E-02) (Fig. 3B). Both values were in the
range previously reported for healthy subjects.
Heritable cardiac and autonomic effects of human
SLC35F3 genetic variation in twin pairs. Subjects with
profound thiamine deﬁciency experience both cardiovascularTable 3
SBP/DBP Determination by SLC35F3 Tagging Variant rs168
2 Independent Study Groups
Group Alleles, Minor/Major MAF. % n Trait
ICBP A/C 0.8 27,865 SBP
KWE1þ2 A/C 0.7 1,951 SBP
Overall A/C 0.8 29,816 SBP
ICBP A/C 0.8 29,452 DBP
KWE1þ2 A/C 0.7 1,944 DBP
Overall A/C 0.8 31,396 DBP
Covariates in these analyses were age, sex, and BMI, and BP values in the hypertensive subjects were a
BMI ¼ body mass index; BP ¼ blood pressure; DBP ¼ diastolic blood pressure; ICBP ¼ International
population BP-extreme samples; MAF ¼ minor allele frequency; SBP ¼ systolic blood pressure.(wet beriberi) and neurologic (dry beriberi) manifestations of
the deﬁciency (35). We, therefore, examined the inﬂuence of
SLC35F3 on heritable cardiac and autonomic traits in a
series of twin pairs. Trait heritability (h2 ¼ VG/VP, where
VG is genetic variance and VP is total phenotypic variance),
estimated from twin pair variance components in SOLAR
(25), is given in Table 4; each trait displayed substantial
heritable determination.
Among cardiac traits (Table 4, Fig. 4A), the
rs17514104 T allele conferred an increase in SVI (p ¼
0.017), with a borderline change in CI (p ¼ 0.065) and a
corresponding fall in SVRI (p ¼ 0.027). Among pressor
traits (Table 4, Fig. 4B), the T allele conferred an increase
in the DBP response to cold stress (p ¼ 0.0036), as well as
the post-stress/ﬁnal DBP (p ¼ 0.027). Among neuroen-
docrine biochemical traits (Table 4, Fig. 4C), the T allele
conferred a decline in secretoneurin (neuroendocrine
secretogranin II fragment) secretion (p ¼ 0.0083). Finally,
among autonomic neural traits (Table 4), baroreceptor
slope (an integrated afferent/efferent reﬂex arc) was un-
changed. False discovery rate analysis indicated that sig-
niﬁcance was preserved after accounting for the multiple
phenotype tests. The second (lower MAF) SLC35F3
SNP, rs16842784, also affected HR (p ¼ 0.009) and CI
(p ¼ 0.007).
Thus, genotype-associated trait changes were primarily
cardiac rather than neurological. The relatively young age
of this phenotyped twin/sibling cohort (Table 1) should be
considered in the interpretation of their cardiovascular
data.42784: Replication by Meta-Analysis Across
Model Beta (Slope per Allele) SE (of Beta) p Value
Additive –4.986 1.413 4.18E-04
Additive –7.092 3.140 1.10E-02
Additive –5.341 1.289 <1.00E-04
Additive –3.340 0.886 1.64E-04
Additive –5.394 2.359 8.00E-03
Additive –3.594 0.829 <1.00E-04
djusted for medications, as described in the Methods section.
Collaboration for Blood Pressure Genome-Wide Association Studies; KWE1þ2 ¼ ﬁrst and second
Figure 3 SLC35F3 and Thiamine Metabolism
(A) Uptake of [3H]-thiamine by expression of human SLC35F3 cDNA in Escherichia
coli. Augmentation of [3H]-thiamine uptake was w3.3-fold (p ¼ 3.4E-04). The
results were normalized to E. coli growth in the sample (A550). (B) SLC35F3
genotype (C/C vs. T/T homozygosity at rs17514104): effect on blood thiamine
concentration in twins and siblings.
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1550Physical characteristics of subjects with rs17514104 T/T
homozygosity, or altered cardiac and vascular function.
We proﬁled each group we studied (twin pairs; population
BP extremes, samples 1 and 2) to test whether there were
readily identiﬁable demographic or clinical signatures of the
underlying genotype. The twins were proﬁled for cardiac
and vascular function; stratiﬁcation of the twins/siblings by
rs17514104 diploid genotype did not reveal differences (all,
p > 0.15 by ANOVA) in age, sex, body mass index, height,
or weight. Within the BP-extreme samples, stratiﬁcation of
either cohort 1 (n ¼ 934) or cohort 2 (n ¼ 1,072) by
rs17514104 diploid genotype did not reveal any differences(all, p > 0.05 by ANOVA) in age, sex, body mass index,
height, or weight.
Hematologic effects of human SLC35F3 genetic variation.
Because patients with other thiamine transporter (SLC19A2,
SLC19A3) mutations may exhibit megaloblastic anemia, our
subjects from the population BP-extreme samples (Fig. 1)
also had determination of the following hematologic traits:
hemoglobin, hematocrit, mean corpuscular volume, ferritin,
and transferrin saturation. None of these traits was inﬂu-
enced by SLC35F3 rs17514104 genotype (all nonsigniﬁ-
cant) in our subjects, which is perhaps not surprising in that
depletions of erythrocyte thiamine in our subjects (p ¼
3.0E-02) (Fig. 3B) still remained within the typical range of
normal.
AEI (allele-speciﬁc expression) at SLC35F3. AEI can
provide independent evidence that a cis-QTL does exist at a
locus, such as SLC35F3 (see Methods section).
HUMAN. Two nearby SNP variants (separated by only 501 bp;
LD as D0: 1.0) (Online Table 2) within the SLC35F3 locus
(both in intron 2) achieved substantial signiﬁcance in their
effects on SLC35F3 transcript abundance in CEU lympho-
blastoid cells (Online Table 4): rs10910399 (p ¼ 4.80E-07;
R2: 0.4005; C-allele overexpressed) and rs12029247 (p ¼
5.92E-07; R2: 0.3956; A-allele overexpressed). Thus these
2 SNPs accounted for w40% of the variance in transcript
abundance. The relative positions of these 2 AEI SNPs are
given in Online Table 2. Notably, these 2 AEI SNPs were
within 78,974 bp of the BP-tagging SNPs (all 4 in intron
2 within the same LD block), with LD estimated at D0 0.406.
However, neither of these 2 AEI SNPs predicted either SBP
or DBP in the ICBP cohort (p > 0.2 in each case).
RODENT (MOUSE). AEI was consistently observed at
SLC35F3 in F1 strains constructed from inbred mouse
strains. Six F1 strains (all possible pairings) were generated
from parental strains A/J (A), C3H/HeJ (C), C57BL/6NJ
(B), and DBA/2J (D). We observed strong signals of AEI in
4 of the 6 groups of F1 animals: AxB, AxD, HxB, and
HxD. The AEI signal was observed from 2 SNPs
(Chr8:128874317 and Chr8:128904545). For F1s AxH and
BxD, the SNPs are homozygous, preventing our ability to
observe AEI. However, for the 4 of F1s (AxB, AxD, HxB,
and HxD) where the SNPs were heterozygous, the ratio of
intensities of the 2 alleles from the RNA hybridization was
signiﬁcantly different from the ratio of intensities of the
2 alleles from the DNA hybridization (p < 0.0001),
providing evidence of AEI at this locus.Discussion
Overview. Hypertension is perhaps the most common and
ultimately fatal of the cardiovascular risk factors (1). Com-
plex traits (36) such as hypertension remain largely enig-
matic in cause, with evidence for both hereditary and
environmental determinants. Twin and family studies sug-
gest substantial heritability (h2) of BP traits, yet the genes
Table 4 SLC35F3 Variant rs17514104: Effect on Heritable Autonomic Traits in Twins and Siblings*
Category/Trait
Trait Heritability (h2)y
in Twin Pairs
(n ¼ 338)
rs17514104 (C/T)
Diploid Genotype,
mean  SEM
(n ¼ 399z)
p Value FDRxEstimate  SEM p Value
C/C
(n ¼ 225)
C/T
(n ¼ 147)
T/T
(n ¼ 36)
Biochemical
Plasma secretoneurin (SCG2 fragment), nM 0.73  0.04 3.08E-26k 0.137  0.0029 0.126  0.0034 0.124  0.0065 0.0083k 0.017k
Physiological/hemodynamic (resting)
Heart rate, beats/min 0.31  0.07 3.94E-05k 71.2  1.44 74.6  1.62 72.2  2.42 0.413 0.184
CI, l/min/m2 0.71  0.04 2.51E-19k 2.73  0.033 2.78  0.041 2.86  0.081 0.065 0.037k
SVI,{ ml/min/m2 0.66  0.05 1.81E-17k 39.3  0.31 39.6  0.35 41.1  0.77 0.017k 0.023k
SVRI,{ dynes/s/cm5/m2 0.55  0.06 7.70E-12k 1517  20.7 1500  27.3 1411  49.1 0.027k 0.027k
Autonomic: baroreceptor slope, ms/mm Hg
Upward deﬂections 0.25  0.08 1.91E-03k 15.1  0.67 14.2  0.69 14.1  1.06 0.730 0.265
Downward deﬂections 0.37  0.08 6.30E-06k 11.8  0.45 11.5  0.50 11.7  0.94 0.718 0.287
Environmental stress (cold pressor test),
mm Hg
Delta-SBP 0.65  0.05 2.60E-16k 11.0  1.74 14.3  2.03 18.5  5.57 0.053 0.035d
Delta-DBP 0.54  0.06 7.52E-11k 8.6  1.06 11.5  1.24 16.6  2.82 0.0036k 0.014k
Post-SBP 0.29  0.07 1.48E-04k 128.2  2.4 131.2  3.13 132.6  6.50 0.142 0.071
Post-DBP 0.29  0.08 1.67E-04k 72.1  1.42 75.5  1.66 77.8  3.68 0.027k 0.027k
*Descriptive statistics were computed in twins and siblings using GEE in SAS (SAS Institute Inc., Cary, North Carolina). yHeritability (h2) was estimated from variance components in twins using Sequential
Oligogenic Linkage Analysis Routines (SOLAR) software (Texas Biomedical Research Institute, San Antonio, Texas). zSome subjects had >1 genotype. xFDR ¼ false discovery rate: In consideration of testing
the effects of multiple correlated alleles (or diploid genotypes) at a locus on a trait, we employed estimation of the FDR to minimize false negative results while maximizing true positive results, using the
Excel calculator of FDR from p values, at http://www.rowett.ac.uk/wgwh/fdr.html. Twin and sibling analyses were adjusted for sex and age. kp < 0.05. {Hemodynamic value (cardiac output or systemic
vascular resistance) normalized to body surface area (in m2).
CI ¼ cardiac index; DBP ¼ diastolic blood pressure; SBP ¼ systolic blood pressure; SVI ¼ stroke volume index; SVRI ¼ systemic vascular resistance index.
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1551involved in the bulk of BP variance in the population remain
elusive (37). Although particular (and relatively uncommon)
families display Mendelian cosegregation of hypertension
with alterations in renal electrolyte transport (5), heritable
BP variation in the population remains largely unaccounted
for, despite recent successes in genome-wide association of
large population samples (6).
Here we harnessed the power of trait extremes (38)
coupled with a pooled genome-wide association strategy
(9) to approach genetic determinants of hypertension in
humans. Exploiting the statistical power that is possible with
a very large sample size, we selected subjects through a sam-
pling design with the power to detect small contributions to
BP variation, ascertaining subjects within the highest- and
lowest-ﬁfth percentiles of BP in a primary care setting in
southern California using a large community database
(>53,000 subjects) of men and women whose BP was mea-
sured at routine health maintenance visits. Genomic DNA
pooling is an effective initial strategy that has been successful
in detecting genetic associations in amyotrophic lateral
sclerosis (39), memory performance (40), progressive supra-
nuclear palsy (41), multiple sclerosis (42), andmelanoma (43).
By these strategies, we identiﬁed a novel BP association on
chromosome 1q42, within the SLC35F3 locus encoding a
previously uncharacterized solute transporter with homology
to an unspeciﬁed thiamine transporter in yeast; we then
documented that SLC35F3 can catalyze thiamine (vitamin
B1) transport, and that risk-allele homozygotes displayeddepletion in blood thiamine content. AEI conﬁrmed that cis
variation at the SLC35F3 locus inﬂuenced gene expression,
and both the clinical marker-on-hypertension effect and
the AEI effect resulted from allelic variation in SLC35F3
intron 2.
Although the involvement of SLC35F3 in hypertension is
an emerging proposal, the picture now derives from multiple
lines of evidence:
 Initial pooled association was found with both Affy-
metrix and Illumina chips.
 Association was veriﬁed by individual genotyping in
the same population sample with BP extremes.
 Association was extended by meta-analysis into an
independent BP-extreme sample from the same pop-
ulation, as well as a new population.
 “Intermediate” (or pathogenic precursor) phenotypes
for hypertension, such as cold stress–induced change
in DBP and post-stress DBP observed in the twin and
sibling pairs, provide a physiological basis for the
SLC35F3 association.
 SLC35F3 may encode a novel thiamine transporter, as
evidenced by depletion of in vivo blood thiamine
stores, and catalysis of in vitro bacterial uptake of
[3H]-thiamine.
Role of thiamine transport and SLC35F3 in hypertension
risk. We were able to document that SLC35F3 can mediate
thiamine transport and that risk-allele homozygotes (T/T)
Figure 4
SLC35F3 and Hypertension: Effects on Early Patho-
genic (or “Intermediate”) Traits in Twins and Siblings
Effects of SLC35F3 variant rs17514104 on (A) systemic vascular resistance
(SVR) and stroke volume, (B) change in diastolic blood pressure (DBP) and ﬁnal
DBP during cold stress, and (C) sympathochromafﬁn exocytosis (secretion of
SCG2 fragment secretoneurin) and SVR. Twin and sibling analyses were adjusted
for sex and age. HWE ¼ Hardy-Weinberg equilibrium.
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afﬁnity thiamine transporters are known: SLC19A2 and
SLC19A3. Rare Mendelian deﬁciency of SLC19A2 leads to
thiamine-responsive megaloblastic anemia (with diabetes
and deafness) (44); however, our SLC35F3 risk allele was
not associated with alterations in hemoglobin or mean
corpuscular volume. Rare variants at SLC19A3 cause auto-
somal recessive basal ganglia disease (45). We have not yet
characterized the relative afﬁnity or abundance of SLC35F3
in comparison to the better characterized thiamine trans-
porters SLC19A2 and SLC19A3, particularly in relevant
cells in brain, heart, and blood vessels.
Because thiamine deﬁciency can cause a spectrum of
phenotypes, from cardiovascular (wet beriberi) to neurologic
(dry beriberi), we evaluated such traits in a series of twins and
siblings and found that such traits were heritable, and the
SLC35F3 risk (T) allele was associated with alterations of
cardiac stroke volume and SVR, as well as pressor responses,
although not neural reﬂex control of the circulation. Thus,
the modest thiamine decrement we observed here apparently
does have hemodynamic (although not autonomic) conse-
quences, consistent with those seen in wet beriberi.
Thiamine (vitamin B1) replacement or supplementation
reportedly corrects abnormalities of both BP and glucose
metabolism in the CD36 (fatty acid translocase)-defective
spontaneously hypertensive rat (SHR) (38). In this model,
thiamine repletion not only corrected glucose oxidation,
hyperinsulinemia, and elevated BP, but also decreased
expression of mRNAs encoding angiotensin-converting
enzyme, angiotensin, and the angiotensin II type 1 receptor
(38). Also of note for our human cardiovascular and auto-
nomic ﬁndings on SLC35F3, dietary depletion of thiamine
in the SHR (38) resulted primarily in cardiovascular signs of
wet beriberi, consistent with our cardiac ﬁndings in twins and
siblings. The SLC35F3 locus also lies within the conﬁdence
interval (rat chromosome 19; human chromosomes 1q42.13–
1q42.3) for linkage to SBP at rat BP QTL 32 (Bp32) in
recombinant inbred strains from an HXBxBXH cross (46),
wherein the hypertensive strain is the SHR.
In humans, thiamine administration reportedly improves
endothelium-dependent vasodilation (47); an older report
suggested a beneﬁcial effect of thiamine on BP in human
hypertension (48), and more recently thiamine lowered SBP
in elderly patients with biochemically documented subclin-
ical thiamine deﬁciency (49), for which diuretic use may be a
risk factor (50).
Why might thiamine exert such beneﬁcial effects in
hypertension? In addition to potential repair of the wet
beriberi lesions noted earlier, analyses of the transcriptome
in rodent genetic models of hypertension reveal widespread
changes in mRNAs encoding components of carbohydrate
intermediary metabolism (51–53), including the thiamine-
dependent transketolase step in the pentose phosphate
pathway.
Functional genetic variation at SLC35F3? What genetic
variant(s) at SLC35F3 confers functional change on the gene,
Figure 5 Human SLC35F3 Genetic Variation
Hypothetical schema of the effects of SLC35F3 polymorphism on thiamine
regulation and cardiovascular disease. BP ¼ blood pressure.
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locus on chromosome 1q42, common nonsynonymous (amino
acid replacement) variation has not been detected at SLC35F3
(NCBI dbSNP), despite extensive exome sequencing of 2n ¼
4,504 chromosomes as part of the National Heart, Lung
and Blood Institute Exome Sequencing Project, as well as
sequencing across the entire region in 2n¼ 358 chromosomes
within the NCBI’s 1000 Genomes Project. Thus, the precise
genetic variant(s) underlying the thiamine and BP traits in this
report remains elusive, but is therefore likely to be noncoding
(and perhaps regulatory). Notably, both the BP-associated
SNPs (rs16842784, rs17514104) and the SNPs displaying
AEI for transcript abundance (rs10910399, rs12029247)
(Online Table 2) are contained within a 78,974-bp stretch
within intron 2 (Online Table 2), and each is in LD with the
others (minimum D0: 0.406). Thus, a relatively circumscribed
region of SLC35F3 seems to harbor alleles’ contribution to
variance in both BP and transcript abundance.
The peak genetic association within SLC35F3 intron 2
suggests splice variation as a possible genetic culprit; indeed,
based on transcript and expressed sequence tag, splice variation
in this region of SLC35F3 does occur, resulting in alternative
retention/exclusion of RefSeq (NM_173508) exon 1, 2, or 3.
A micro-RNA gene encoding hsa-miR-4671 is
embedded within intron 3 of SLC35F3; however, the
downstream targets of hsa-miR-4671 are not yet deﬁned,
and thus we did not pursue this micro-RNA in light of our
positive ﬁndings on thiamine transport and storage.
The relative abundance of SLC35F3 expression across
human tissues has been reported (54): SLC35F3 is widely
expressed across tissues pertinent to BP control, such as
brain (maximal in cerebellum), adipocytes, heart, kidney,
and smooth muscle. In the mouse transcriptome, SLC35F3
is most highly expressed in the central nervous system: ciliary
bodies > retinal pigment epithelium > iris > dorsal striatum
> nucleus accumbens > spinal cord.
Advantages and limitations of this study. STRENGTHS. This
study began with a genome-wide approach in subjects with the
most extreme BP values in the population, an approach that
has enhanced power to detect genetic marker-on-trait associ-
ation, even when the genotype contributes only modestly to
total trait variation (38). Evidence for involvement of the
SLC35F3 gene in hypertension then emerged from multiple
lines of evidence: clinical, genetic, and biochemical.
CAVEATS. Our studies on SLC35F3 in hypertension and
autonomic physiology were conducted in subjects of limited
diversity in biogeographic ancestry; studies of additional
ethnic or population groups would be required to evaluate
whether these SLC35F3 results are of more general impor-
tance across the overall population. Caution should be
exercised in interpreting the results of pooled genetic asso-
ciation studies; however, we undertook individual genotyp-
ing, based on preliminary pooling results, in order to apply
appropriate statistical tests to our results. “Intermediate”
cardiovascular traits, such as CO, were studied in a relativelyyoung cohort of twins and siblings (Table 1), on average
w18 years younger than the population BP-extreme sample
andw10 years younger than the ICBP; because the relative
contribution of elevated CO to hypertension declines with
advancing age, additional cardiovascular (output and resis-
tance) data in older subjects would be useful. Despite initial
ﬁndings that SLC35F3 is involved in thiamine transport, we
do not yet understand the details of such action, including
the afﬁnity, capacity, and selectivity of SLC35F3 for its
thiamine substrate, nor have we examined the effect of
thiamine replacement upon BP or its precursor traits,
although previous work in animals (38) and humans (48)
suggests a beneﬁcial effect.Conclusions and Perspectives
We coupled 2 novel strategies, quantitative trait-extreme
sampling and pooled genome-wide association, to discover
a new hypertension-susceptibility locus, uncovering a pre-
viously unsuspected thiamine transporter whose genetic
variants predicted several disturbances in cardiac and auto-
nomic function. Figure 5 integrates our ﬁndings into an
overall hypothetical schema. The results have implications
for the heritability of the BP trait and the pathogenesis
systemic hypertension and open up new approaches to the
rational prevention or treatment of the trait.
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